| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于预计触发可转债转股价格向下修正条件 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 12.00 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 5、截至 2025 年 7 月 21 日，蓝帆医疗股份有限公司（以下简称"公司"）股票已 有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发"蓝帆转债"转股价格向 下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 2 ...

2025年7月14日， 蓝帆医疗股份有限公司 （股票代码：002382）发布了2025年半年度业绩预告。 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损: 15,000 万元 - 10,000 万元 | 亏损:16,021.68 万元 | | | 比上年同期增长:6.38% - 37.58% | | | 扣除非经常性损益 | 亏损: 23,000 万元 - 17,000 万元 | 亏损:19,640.18 | | 后的净利润 | | 万元 | | | 比上年同期增长: -17.11% -13.44% | | | 基本每股收益 | 亏损:0.15 元/股 - 0.10 元/股 | 亏损:0.16 元/股 | 根据公告，公司预计2025年上半年实现归属于上市公司股东的净利润为 亏损1亿元至1.5亿元 ，较上年同期 亏损1.6亿元有所收窄，同比 增长6.38%至37.58% 。扣除非经常性损益后的净利润 亏损1.7亿元至2.3亿元 ，同比变动幅度为-17.11%至13.44%。 业绩变动原因 # 关于蓝帆医疗 护理事业部：以 急救包 为核 ...

Core Viewpoint - Bluefan Medical (002382.SZ) is expected to narrow its net loss in the first half of 2025 to between 1 billion and 1.5 billion yuan, with a reduction of 6.38% compared to the previous period, driven by the growth of new products and a significant increase in sales revenue from its cardiovascular division [1] Group 1: Financial Performance - The company anticipates a sales revenue exceeding 690 million yuan from its cardiovascular division in the first half of 2025, representing a year-on-year growth of over 20% [1] - The company reported a fair value loss of approximately 120 million yuan due to the valuation changes of its investment in Suzhou Tongxin Medical Technology Co., Ltd., which does not involve cash outflow [1] - Financial expenses of 25 million yuan were incurred in the second quarter of 2025 due to strategic investment matters related to its subsidiary, which also does not involve cash outflow [1] Group 2: Business Strategy and Innovation - Since entering the high-end medical device sector through the acquisition of Bosheng International in 2018, Bluefan Medical has shifted its focus from low-value consumables to high-value consumables, with over 2 billion yuan invested in R&D [2] - The company has been recognized in the field of innovative medical devices, particularly in the area of intravascular shockwave (IVL) technology, which is crucial for treating calcified vascular lesions [2] - Bluefan Medical has developed proprietary electrode technology that operates at lower voltages while achieving higher acoustic pressure, enhancing treatment efficacy compared to similar products [3] Group 3: Market Expansion - The company plans to leverage its existing overseas teams, channels, and stable customer relationships to expand its market presence, focusing on regions where local registration qualifications can be accepted [3] - Future plans include conducting larger-scale post-market clinical studies to lead the operational concepts and standardized treatment guidelines for IVL in the global market [3]

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 2025年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 6 月 30 日 2、预计的业绩： | | | √亏损 □扭亏为盈 □同向上升 □同向下降 | 项 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损：15,000 | 万元–10,000 | 万元 | 亏损：16,021.68 万元 | | | 比上年同期增长：6.38% - | | 37.58% | | | 扣除非经常性损益 | 亏损：23,000 | 万元–17,000 | 万元 | 亏损：19,640.18 | | 后的净利润 | | | | 万元 | | | 比上年同期增长：-17.11% ...

Core Viewpoint - The PTCA balloon industry in China is experiencing steady growth due to the increasing prevalence of cardiovascular diseases, the expansion of coronary intervention treatments, and the rise of domestic medical device manufacturers. The market size is projected to grow from 1.059 billion yuan in 2021 to 1.366 billion yuan in 2024, with expectations to exceed 2.274 billion yuan by 2030 [1][11]. Industry Overview - PTCA balloons are medical devices used in cardiovascular interventions to dilate narrowed or blocked coronary arteries, improving blood flow and myocardial supply [1]. - The industry chain consists of upstream raw materials and equipment supply, midstream production, and downstream application in various medical institutions for treating cardiovascular diseases [2]. Industry Environment - The incidence of coronary artery disease (CAD) is rising in China, with the number of patients increasing from 25.272 million in 2020 to 27.953 million in 2024, and projected to exceed 30 million by 2030 [4]. - The mortality rate for CAD has also increased significantly, indicating a growing demand for treatment options [4]. Industry Status - Percutaneous coronary intervention (PCI) is a key treatment method for CAD, with a record of 1.63 million PCI procedures performed in 2023, marking a growth rate of 26.44% [7]. - Despite the increasing number of PCI procedures, the market penetration rate in China remains low at 690.9 procedures per million people, compared to 3022.1 in the U.S., suggesting significant growth potential [9]. Competitive Landscape - The global PTCA balloon market is dominated by international giants like Boston Scientific and Medtronic, which hold over 60% market share, particularly in high-end drug-eluting balloons [13]. - Domestic companies account for 60% of the number of firms but only 40% of the market share, indicating a competitive landscape where local firms are striving to catch up through innovation [13]. Future Trends - The industry is witnessing significant technological innovation and product upgrades, with new polymer materials enhancing balloon performance and the introduction of drug-coated balloons reducing the risk of restenosis [19]. - The trend towards domestic substitution is accelerating, with local companies like MicroPort and Lepu Medical increasing their market share due to improved product quality and performance [20]. - The demand for PTCA balloons is expected to grow as their application expands beyond traditional coronary disease treatment to include peripheral and intracranial vascular diseases [21].

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng (Qingdao) Law Firm confirms that the second extraordinary general meeting of shareholders of Bluestar Medical Co., Ltd. held on July 7, 2025, complied with relevant laws and regulations, and the voting procedures were valid [2][5][7]. Group 1: Meeting Procedures - The notice for the extraordinary general meeting included details such as the convenor, date, time, and voting methods, ensuring compliance with legal requirements [3][4]. - The meeting was held on July 7, 2025, at 14:00 in the Bluestar Medical office center, with a combination of on-site and online voting [4][5]. Group 2: Attendance and Voting - A total of 11 shareholders attended the meeting in person, representing 259,959,601 shares, which is 25.8119% of the total shares [5][6]. - An additional 574 shareholders participated via online voting, representing 21,077,733 shares [5][6]. - The total number of participants, including both on-site and online, was 578, with a combined share representation of 281,037,334 shares [6]. Group 3: Resolutions and Voting Results - The main resolution discussed was the proposal to lower the conversion price of "Bluestar Convertible Bonds," which was consistent with the agenda provided in the meeting notice [6]. - The voting results showed that 265,958,829 shares approved the resolution, with 58.5152% of small investors voting in favor [6][7].

Core Viewpoint - The company has decided to lower the conversion price of its convertible bonds, "蓝帆转债," to 12.00 CNY per share, effective from July 8, 2025, due to stock price performance and future development considerations [3][6]. Group 1: Convertible Bond Issuance and Adjustment - The total amount of the convertible bonds issued by the company was 314.404 million CNY, approved by the China Securities Regulatory Commission [1]. - The initial conversion price was set at 17.79 CNY per share, which was later adjusted to 18.64 CNY per share after the company repurchased and canceled 48,148,336 shares as part of a performance compensation plan [2][3]. - The conversion price was further adjusted to 12.50 CNY per share on May 21, 2024, following the approval of the shareholders [3][4]. Group 2: Conditions for Price Adjustment - The adjustment of the conversion price is triggered when the closing price of the company's stock is below the current conversion price for at least 15 out of 30 consecutive trading days [4][5]. - The new conversion price must not be lower than the higher of the average trading price over the 20 days prior to the shareholders' meeting and the last trading day's price, as well as not lower than the latest audited net asset value per share [4][5]. Group 3: Recent Developments - The average trading price of the company's stock was 5.63 CNY per share over the 20 days prior to the second extraordinary shareholders' meeting in 2025, and 5.94 CNY on the last trading day before the meeting [5][6]. - The latest audited net asset value per share was reported at 8.13 CNY, which sets a minimum threshold for the conversion price adjustment [5].

| 证券代码：002382 | 证券简称：蓝帆医疗 公告编号：2025-057 | | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、债券代码：128108，债券简称：蓝帆转债； 2、修正前转股价格：12.50 元/股； 3、修正后转股价格：12.00 元/股； 4、修正后转股价格生效日期：2025 年 7 月 8 日。 蓝帆医疗股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开第六届董事会 第二十五次会议，审议通过了《关于向下修正"蓝帆转债"转股价格的议案》，现将相 关事项公告如下： 一、可转债发行上市基本情况 蓝帆医疗股份有限公司 关于向下修正"蓝帆转债"转股价格的公告 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了 3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值 100 元，发 行总额314,404 万元。 （二）可转债上市情况 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项参与度， 本次股东会审议议案对中小投资者单独计票。中小投资者是指除上市公司董事、高级 管理人员以及单独或合计持有上市公司5%以上股份的股东以外的其他股东。 2、本次股东会未出现否决议案的情形。 3、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议的通知：蓝帆医疗股份有限公司（以下简称"公司"）于2025年6月20日在 《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）上刊登了会议通知。 2、会议召开的日期、时间： （1）现场会议时间：2025 年 7 月 7 日（星期一）下 ...

上海锦天城（青岛）律师事务所 关于蓝帆医疗股份有限公司 2025 年第二次临时股东会的 上海锦天城（青岛）律师事务所 关于蓝帆医疗股份有限公司 2025 年第二次临时股东会的 法律意见书 致蓝帆医疗股份有限公司： 上海锦天城（青岛）律师事务所（以下简称"本所"）接受蓝帆医疗股份 有限公司（以下简称"公司"或"蓝帆医疗"）的委托，指派冉令帅、孙一杰 律师出席了公司于 2025 年 7 月 7 日召开的 2025 年第二次临时股东会（以下简 称"本次股东会"）。现根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）和《上市 公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、规 范性文件以及《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"） 的规定，对本次股东会会议的召集、召开程序是否符合法律、行政法规、规范 性文件和《公司章程》的规定，出席会议人员的资格、召集人资格是否合法有 效，表决程序与表决结果是否合法有效出具本法律意见书。 法律意见书 地址：青岛市市南区香港 ...